Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia.
Heparin is considered necessary during percutaneous coronary interventions; however, heparin is contraindicated in patients with heparin-induced thrombocytopenia and/or heparin antibodies. We describe the successful use of the heparinoid Orgaran (danaparoid sodium) in addition to abciximab (ReoPro) in a patient with heparin antibodies who required rotational atherectomy.
Hale
L P
LP
Section on Hematology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA. phaleobi@earthlink.net
Smith
K
K
Braden
G A
GA
Owen
J
J
D000077284:Abciximab; D000906:Antibodies / Q000032:analysis; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D017225:Atherectomy, Coronary / Q000379:methods; D001777:Blood Coagulation / Q000187:drug effects; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology; D006496:Heparinoids / Q000627:therapeutic use*; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D007432:Intraoperative Period; D008297:Male; D008875:Middle Aged; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced* / Q000276:immunology
D000077284:Abciximab; D000906:Antibodies; D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006493:Heparin; D006496:Heparinoids; D006497:Heparan Sulfate; D007140:Immunoglobulin Fab Fragments; C035838:danaparoid